Prof Xavier Golay

Gold Standard Phantoms Limited

Speaker Biography: (max 200 words, no bullet points)
Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents. Xavier is originally from Switzerland. He started working on Arterial Spin Labelling during his PhD in the Mid ‘90s and eventually became one of the world’s most renowned MRI specialists in this field. In addition to his academic career, Xavier spent two years working for Philips Healthcare in Singapore. He is currently the Vice Dean for Enterprise of the Faculty of Brain Sciences and, as such, is in charge of facilitating technology transfer within the faculty, by means of IP licensing, consulting activities or establishment of spinout companies.
In the last four years, Xavier co-founded both Imgenious and Gold Standard Phantoms together with Aaron Oliver-Taylor and Tom Hampshire.
Xavier’s role is to oversee the whole operation at GSP and in particular to help providing the support and network necessary to such a small enterprise. He is leading on most legal and financial aspects of the business, and provides guidance to the whole team.

dont miss

Reference standards for establishment of quantitative imaging biomarkers in neurology

At Gold Standard Phantoms, our mission is to enable medical imaging to move from a pattern recognition-based technique to a quantitative and reproducible scientific measurement methodology called quantitative medical imaging. We are working in collaboration with the main stakeholders in the field to provide a one-stop-shop integrated solution for Quantitative Medical Imaging.

Quantitative Medical Imaging as remained elusive, in spite of a global effort by the international community over the last 30 years, and intrinsically quantitative methods such as perfusion imaging are still not used on a daily clinical practice by the lack of internationally accepted standards, governance structure and knowledge.

This has tremendous implications in neurology, as quantitative image-based biomarkers could play a significant role in establishing new treatment for neurodegenerative diseases as primary tools for the stratification of patients for entering clinical trials, and for improved diagnosis of patients prior to treatment once these disease modifying treatments exist.


  • Tamsin Reed: Speaking at the European Neurological Convention

    Tamsin Reed
    Wellington Hospital, London

    Maximising outcomes using advanced technology in Neurological Rehabilitation.

  • Dr Anne Wright: Speaking at the European Neurological Convention

    Dr Anne Wright
    Evelina London Children’s Hospital, Guy’s and St Thomas’ NHS foundation Trust

    Neuromodulation for Incontinence in Children

  • Amanda Denton: Speaking at the European Neurological Convention

    Amanda Denton
    Plymouth University

    Rehabilitation of gait in people with Hereditary Spastic Paraparesis:

  • Tina Soulis: Speaking at the European Neurological Convention

    Tina Soulis
    Neuroscience Trials Australia

    Strategies in CNS Drug and Device Development: The Australian Advantage

  • Maggie Sargent: Speaking at the European Neurological Convention

    Maggie Sargent
    Maggie Sargent & Associates

    The Journey- Having a purpose in life following Brain Injury